Tonix Pharmaceuticals Presents Data on TNX-801 Mpox Vaccine
Tonix Pharmaceuticals Holding Corp. presented data on TNX-801, a live virus vaccine investigational candidate, at the World Vaccine Congress–Europe 2025.
TNX-801 is designed to provide durable protection against mpox and smallpox, demonstrating favorable safety, immunogenicity, and long-term protection in multiple preclinical models.
- TNX-801 is a live virus vaccine investigational candidate.
- Designed to provide durable protection against mpox and smallpox.
- Demonstrated favorable safety, immunogenicity, and long-term protection.
“Safety, Durability and Protection of a Single-Dose TNX-801 Mpox Vaccine”
A copy of the presentation is available on the Tonix website at www.tonixpharma.com.
Author's summary: Tonix presents data on TNX-801 vaccine candidate.
More News
- Nintendo Reportedly Asking Manufacturers to Produce 25m Switch 2 Units By March | TechRaptor
- THE SIMPSONS: Season 37, Episode 3: Treehouse of Horror XXXVI [Fox]
- Football: Nevis caps off regular season with loss
- Israeli airstrikes killed 1 and injured 7 in Lebanon despite ceasefire – Ya Libnan
- A classified network of SpaceX satellites is emitting a mysterious signal
- When faith, science and politics collide
- Tipp GAA club to donate lotto earnings to help a family of a club member undergoing treatment
- The 11 Best Body-Swap Movies, Ranked | Features | Roger Ebert
- ‘Building community’: Hundreds attend inaugural LIC Wellness Fest – QNS
- Jaxson Hayes wants to grant Luka Doncic a wish few saw coming